Displaying 60 (all) recruiting clinical trials.
-
A Master Protocol for the Multi-Cohort Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
This master protocol is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies ... -
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer
Single Arm Phase Ib study at fixed dose of standard of care chemotherapy and anti PD1 and IL1b to evaluate the safety and preliminary toxicity ... -
A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers ... -
Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors
To evaluate the safety and tolerability of RMC-6291 in combination with RMC-6236 in participants with KRASG12C-mutated solid tumors To estimate the MTD and/or RP2DS ... -
Phase 1/1b Multicenter Open-Label Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors -
A Phase 1 Multicenter Open-Label Study of CB-010 a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
T cells are an integral part of the immune system that kills cancer cells in the body. T cells have been harvested from peripheral blood ... -
An open-label phase I dose escalation expansion study of MGY825 in adult patients with advanced non-small cell lung cancer
This study wants to figure out if a new medicine called MGY825 is safe and helpful for patients with advanced non-small cell lung cancer. They ...
-
AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This is a study of a drug called LOXO-435 for patients with advanced solid tumors, specifically focusing on metastatic urothelial cancer (mUC) that has a ...
-
A Phase 1/1b First-In-Human Multi-Part Open-Label Study to Investigate the Safety Tolerability Pharmacokinetics Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable Recurrent or Metastatic) Solid Tumors
This is a study is testing a new drug called DF6215 on patients with tough-to-treat (unresectable, recurrent or metastatic) solid tumors. The goal is to ...
-
A First-in-Human Phase 1a/1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor a Expressing Tumor Cells in Participants with Selected Advanced Solid Tumors
This study will test a new drug called LY4170156, an antibody drug conjugate (ADC) to see how it works in the body, and if it ...